Appendix D: Clinical trial evidence summary for Janssen COVID-19 vaccine.Estimates of vaccine efficacy against asymptomatic infection, by dosing interval (SD/SD seronegative baseline efficacy set) Estimates of vaccine efficacy against the hospitalization, by dosing interval (SD/SD seronegative baseline efficacy set) Estimates of vaccine efficacy against the first occurrence of confirmed COVID-19 beginning after Dose 1 (SD/SD seronegative baseline efficacy set)
Estimates of vaccine efficacy against the first occurrence of confirmed COVID-19 beginning ≥15 days after Dose 2, by dosing interval and age group (SD/SD seronegative baseline efficacy set) Estimates of vaccine efficacy against the first occurrence of confirmed COVID-19 beginning ≥15 days after Dose 2 in all participants, by dosing interval (SD/SD seronegative baseline efficacy set) Appendix C: Clinical trial evidence summary for AstraZeneca Vaxzevria COVID-19 vaccine.Moderna vaccine efficacy against the first occurrence of symptomatic COVID-19 disease after dose 1 Appendix B: Clinical trial evidence summary for Moderna Spikevax COVID-19 vaccine.Pfizer-BioNTech vaccine efficacy against the first occurrence of symptomatic COVID-19 disease after dose 1 and before dose 2 in adolescents 12 to 15 years of age Pfizer-BioNTech vaccine efficacy against the first occurrence of symptomatic COVID-19 disease after dose 1 and before dose 2 in participants 16 years of age and older Appendix A: Clinical trial evidence summary for Pfizer-BioNTech Comirnaty COVID-19 vaccine.Vaccination considerations for types of COVID-19 vaccines authorized for use in Canada Blood products, human immunoglobulin and timing of immunization.Ingredients of authorized COVID-19 vaccines that have been associated with allergic reactions in other products Vaccine safety and adverse events following immunization (AEFI).Concomitant administration with other vaccines.Immunization schedule, by COVID-19 vaccine COVID-19 vaccines authorized for use in Canada Preparations of COVID-19 vaccines authorized for use in Canada.Summary of risk factors for severe outcomes from COVID-19 and increased risk of exposure to COVID-19